Tildrakizumab for treating active psoriatic arthritis [ID6724]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC